Health Care & Life Sciences » Biotechnology | Scancell Holdings PLC

Scancell Holdings PLC | Income Statement

Fiscal year is May-April. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
44.00
39.00
29.10
21.90
32.60
27.60
Gross Income
44.00
39.00
29.10
21.90
32.60
27.60
SG&A Expense
2,140.00
2,458.30
2,930.90
3,021.30
4,516.30
4,914.20
EBIT
2,184.00
2,497.20
2,960.00
3,043.20
4,548.80
4,941.80
Pretax Income
2,154.00
2,468.00
2,828.50
3,029.60
4,495.40
4,939
Income Tax
252.00
245.10
413.90
446.30
950.40
744.50
Consolidated Net Income
1,901.90
2,223.00
2,414.60
2,583.30
3,545.00
4,194.50
Net Income
1,901.90
2,223.00
2,414.60
2,583.30
3,545.00
4,194.50
Net Income After Extraordinaries
1,901.90
2,223.00
2,414.60
2,583.30
3,545.00
4,194.50
Net Income Available to Common
1,901.90
2,223.00
2,414.60
2,583.30
3,545.00
4,194.50
EPS (Basic)
0.01
0.01
0.01
0.01
0.01
0.01
Basic Shares Outstanding
200,427.40
218,042.40
226,344.20
228,229.80
262,329.90
312,726.40
EPS (Diluted)
0.01
0.01
0.01
0.01
0.01
0.01
Diluted Shares Outstanding
200,427.40
218,042.40
226,344.20
228,229.80
262,329.90
312,726.40
EBITDA
2,140.00
2,458.30
2,930.90
3,021.30
4,516.30
4,914.20
Non-Operating Interest Income
30.00
29.20
131.50
13.60
53.40
2.80

About Scancell Holdings

View Profile
Address
John Eccles House
Oxford Oxfordshire OX4 4GP
United Kingdom
Employees -
Website http://scancell.co.uk
Updated 07/08/2019
Scancell Holdings Plc engages in the development of novel therapeutic vaccines for the treatment of cancer. It operates through ImmunoBody and Moditope technology platforms. The company was founded by Lindy Gillian Durrant in 1997 and is headquartered in Oxford, the United Kingdom.